COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective

Abstract Coronavirus disease 2019 (COVID-19) vaccines have yielded definitive prevention and major reductions in morbidity and mortality from severe acute respiratory syndrome coronavirus 2 infection, even in the context of emerging and persistent variants of concern. Newer variants have revealed less vaccine protection against infection and attenuation of vaccine effects on transmission. COVID-19 vaccines still likely reduce transmission compared with not being vaccinated at all, even with variants of concern; however, determining the magnitude of transmission reduction is constrained by the challenges of performing these studies, requiring accurate linkage of infections to vaccine status and timing thereof, particularly within households. In this review, we synthesize the currently available data on the impact of COVID-19 vaccines on infection, serious illness, and transmission; we also identify the challenges and opportunities associated with policy development based on this data.

[1]  R. von Känel,et al.  Associations of employment status with opioid misuse: Evidence from a nationally representative survey in the U.S. , 2022, Journal of psychiatric research.

[2]  D. Barouch,et al.  Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants , 2022, The New England journal of medicine.

[3]  D. Angus,et al.  Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  N. Daneman,et al.  Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada. , 2022, JAMA.

[5]  W. Schaffner,et al.  Hospitalizations of Children and Adolescents with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, July 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[6]  D. Barouch,et al.  Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants , 2022, medRxiv.

[7]  A. Monto,et al.  Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational Study , 2022, medRxiv.

[8]  S. Balter,et al.  SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance — Los Angeles County, California, November 7, 2021–January 8, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[9]  Yawen Jiang,et al.  Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China , 2022, Annals of Internal Medicine.

[10]  D. Barouch,et al.  Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron , 2022, Nature.

[11]  Karl A. Soetebier,et al.  Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[12]  Manish M Patel,et al.  Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021 , 2022, MMWR. Morbidity and mortality weekly report.

[13]  S. Schrag,et al.  Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. , 2022, JAMA.

[14]  K. Bruxvoort,et al.  Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants , 2022, Nature Medicine.

[15]  T. Peto,et al.  Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants , 2022, The New England journal of medicine.

[16]  S. E. Reese,et al.  Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—Nine States, January–September 2021 , 2021, American Journal of Transplantation.

[17]  K. Spiess,et al.  SARS-CoV-2 Omicron VOC Transmission in Danish Households , 2021, medRxiv.

[18]  T. Ndung’u,et al.  Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization , 2021, Nature.

[19]  P. Maes,et al.  Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.

[20]  J. Bhiman,et al.  Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa , 2021, medRxiv.

[21]  K. Mølbak,et al.  Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study , 2021, medRxiv.

[22]  J. Mascola,et al.  Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization , 2021, medRxiv.

[23]  Liyuan Liu,et al.  Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 , 2021, Nature.

[24]  Katherine C DeRuff,et al.  Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak , 2021, Cell.

[25]  S. Kissler,et al.  Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons , 2021, The New England journal of medicine.

[26]  Lindsay N. Carpp,et al.  Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.

[27]  D. Follmann,et al.  Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge , 2021, The New England journal of medicine.

[28]  L. Abu-Raddad,et al.  BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar , 2021, Nature Medicine.

[29]  N. Gupta,et al.  Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses , 2021, The Lancet Infectious Diseases.

[30]  R. Lin,et al.  Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study , 2021, Clinical Microbiology and Infection.

[31]  J. Salomon,et al.  Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison , 2021, The New England journal of medicine.

[32]  M. Yaghoubi,et al.  Systematic review of productivity loss among healthcare workers due to Covid‐19 , 2021, The International journal of health planning and management.

[33]  I. Diamond,et al.  Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK , 2021, Nature Medicine.

[34]  A. Nordström,et al.  Association Between Risk of COVID-19 Infection in Nonimmune Individuals and COVID-19 Immunity in Their Family Members , 2021, JAMA internal medicine.

[35]  O. A. Ogun,et al.  Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study , 2021, The Lancet.

[36]  N. Ferguson,et al.  Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study , 2021, The Lancet Infectious Diseases.

[37]  P. G. Choe,et al.  Work Restrictions for Healthcare Personnel with Potential In-hospital Exposure to SARS-CoV-2: Experience at a Tertiary Hospital , 2021, Journal of Korean medical science.

[38]  J. Tate,et al.  Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison — Texas, July–August 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[39]  J. Mascola,et al.  Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase , 2021, The New England journal of medicine.

[40]  Meei-Li W Huang,et al.  Quantitative measurement of infectious virus in SARS-CoV-2 Alpha, Delta and Epsilon variants reveals higher infectivity (viral titer:RNA ratio) in clinical samples containing the Delta and Epsilon variants , 2021, medRxiv.

[41]  K. Natarajan,et al.  Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[42]  P. McKeigue,et al.  Effect of Vaccination on Transmission of SARS-CoV-2 , 2021, The New England journal of medicine.

[43]  A. Iwasaki,et al.  Prevention of host-to-host transmission by SARS-CoV-2 vaccines , 2021, The Lancet Infectious Diseases.

[44]  J. Starrfelt,et al.  Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[45]  C. Longhurst,et al.  Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce , 2021, The New England journal of medicine.

[46]  Kwok-Hung Chan,et al.  Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3 , 2021, Vaccines.

[47]  R. Link-Gelles,et al.  Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[48]  David W. McDonald,et al.  Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[49]  B. O. Oude Munnink,et al.  Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers , 2021, medRxiv.

[50]  C. Whaley,et al.  Vaccinations Against COVID-19 May Have Averted Up To 140,000 Deaths In The United States. , 2021, Health affairs.

[51]  Y. Liu,et al.  The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus , 2021, Journal of travel medicine.

[52]  Catherine M. Brown,et al.  Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[53]  M. Binnicker Can Testing Predict SARS-CoV-2 Infectivity? The Potential for Certain Methods To Be Surrogates for Replication-Competent Virus , 2021, Journal of clinical microbiology.

[54]  H. D. de Melker,et al.  Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[55]  M. Lipsitch,et al.  Covid-19 Breakthrough Infections in Vaccinated Health Care Workers , 2021, The New England journal of medicine.

[56]  Wildo Navegantes de Araújo,et al.  Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study , 2021, The Lancet Regional Health - Americas.

[57]  R. Myers,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.

[58]  S. Cauchemez,et al.  Impact of BNT162b2 Vaccination and Isolation on SARS-CoV-2 Transmission in Israeli Households: An Observational Study , 2021, medRxiv.

[59]  Forrest W. Crawford,et al.  Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel , 2021, medRxiv.

[60]  H. Schuitemaker,et al.  Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination , 2021, The New England journal of medicine.

[61]  Lu Shi,et al.  Negative Employment Changes During the COVID-19 Pandemic and Psychological Distress , 2021, Journal of occupational and environmental medicine.

[62]  F. Rey,et al.  Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization , 2021, Nature.

[63]  Ross J. Harris,et al.  Effect of Vaccination on Household Transmission of SARS-CoV-2 in England , 2021, The New England journal of medicine.

[64]  H. Schuitemaker,et al.  Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans , 2021, Nature.

[65]  P. Delafontaine,et al.  Ct Values Do Not Predict Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmissibility in College Students , 2021, The Journal of Molecular Diagnostics : JMD.

[66]  Andrew L. Phillips,et al.  Prevention and Attenuation of COVID-19 by BNT162b2 and mRNA-1273 Vaccines , 2021, medRxiv.

[67]  A. Sheikh,et al.  SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness , 2021, The Lancet.

[68]  William T. Harvey,et al.  SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.

[69]  M. Hassany,et al.  Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. , 2021, JAMA.

[70]  J. Guedj,et al.  Quantifying the relationship between SARS-CoV-2 viral load and infectiousness , 2021, medRxiv.

[71]  Scott L. Bain,et al.  COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study , 2021, The Lancet.

[72]  D. Hatzigeorgiou,et al.  Costs associated with COVID-19 in healthcare personnel in Greece: a cost-of-illness analysis , 2021, Journal of Hospital Infection.

[73]  H. Fennema,et al.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.

[74]  Andrew L. Phillips,et al.  Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[75]  D. Bonsall,et al.  Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial , 2021, The Lancet.

[76]  Graham W. Taylor,et al.  Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Nature.

[77]  N. Shah,et al.  Impact of the Coronavirus Disease 2019 (COVID-19) Vaccine on Asymptomatic Infection Among Patients Undergoing Preprocedural COVID-19 Molecular Screening , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[78]  M. Ponga,et al.  Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations , 2021, Scientific Reports.

[79]  P. Gilbert,et al.  Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection , 2021, PLoS pathogens.

[80]  M. Hernán,et al.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting , 2021, The New England journal of medicine.

[81]  A. Goyal,et al.  Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events , 2021, eLife.

[82]  Y. Kreiss,et al.  Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients , 2021, The Lancet.

[83]  A. Venkatakrishnan,et al.  FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system , 2021, medRxiv.

[84]  Charles Y. Tan,et al.  BNT162b vaccines protect rhesus macaques from SARS-CoV-2 , 2021, Nature.

[85]  P. Dormitzer,et al.  Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera , 2021, Science.

[86]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[87]  Carl A. B. Pearson,et al.  Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.

[88]  A. Pollard,et al.  A guide to vaccinology: from basic principles to new developments , 2020, Nature reviews. Immunology.

[89]  H. Tani,et al.  Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients , 2020, PloS one.

[90]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[91]  M. Cevik,et al.  SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis , 2020, The Lancet Microbe.

[92]  Joel C. Miller,et al.  Superspreading events in the transmission dynamics of SARS-CoV-2: Opportunities for interventions and control , 2020, PLoS biology.

[93]  D. Ho,et al.  Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies , 2020, PLoS biology.

[94]  Rebecca J. Loomis,et al.  SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness , 2020, Nature.

[95]  Sebastian Funk,et al.  Extended data: Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China , 2020 .

[96]  Frank Grosveld,et al.  A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.

[97]  N. Guiso,et al.  Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines , 2014, Expert review of vaccines.

[98]  P. Gilbert,et al.  Sieve analysis in HIV-1 vaccine efficacy trials. , 2013, Current opinion in HIV and AIDS.

[99]  M. Lipsitch,et al.  Serotype replacement in disease after pneumococcal vaccination , 2011, The Lancet.

[100]  A. Zuckerman,et al.  Vaccine-induced escape mutant of hepatitis B virus , 1990, The Lancet.

[101]  R. Evans European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).